1. Introduction {#sec1}
===============

Malignant tumors are among the leading causes of morbidity and mortality for people of all ages worldwide \[[@B1], [@B2]\]. Despite the considerable progress in cancer treatments such as immunotherapy and targeted therapy, the survival rate for most cancers is still low \[[@B3], [@B4]\]. Finding potential biomarkers of cancer prognosis and elucidating their role and mechanisms will greatly impact the care of cancer patients.

Long noncoding RNAs (lncRNAs) are transcripts with a length of more than 200 nucleotides and are widely found in nucleus, cytoplasm, and exosome \[[@B5]\]. They usually cannot be translated into specific proteins because they do not have functional open reading frames \[[@B6]\]. Over the past decade, many studies have reported the critical role of such transcripts in physiological processes, like embryogenesis, immune cell activation, blood cell maturation, and cell-to-cell communication \[[@B5], [@B7]--[@B9]\]. Moreover, many lncRNAs are dysregulated in human cancers, and lncRNAs may act as oncogenes or tumor suppressors in tumorigenesis and metastasis processes \[[@B5], [@B10], [@B11]\]. They have been proven to be a novel and promising prognostic biomarker and treatment targets in human cancer \[[@B12], [@B13]\].

Small nucleolar RNA host gene 15 (SNHG15) is a newly discovered LncRNA located on chromosome 7p13 \[[@B14]\]. SNHG15 is reported to be significantly upregulated in a variety of cancer tissues compared with adjacent noncancer tissues \[[@B15]--[@B17]\], and abnormal overexpression of SNHG15 in cancer samples is associated with poor prognosis and high risk of metastasis in different cancers, including breast, colorectal, gastric, and prostate cancers \[[@B15], [@B18]--[@B28]\]. However, the prognostic value of SNHG15 expression in thyroid cancers and glioma is controversial \[[@B29], [@B30]\]. Therefore, we meta-analyzed all relevant publications and TCGA database to achieve a comprehensive understanding of the relationship between SNHG15 expression and cancer patient prognosis and evaluated whether SNHG15 could be a potential biomarker for the prognosis of cancer patients.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search Strategies {#sec2.1}
---------------------------------

Article search was performed in the databases, including PubMed, PMC, EMBASE, Web of Science, and Cochrane Library. The time limit for searching was from the construction of these databases to December 20, 2019. The terms used for the search were as follows: (small nucleolar RNA host gene 15 OR SNHG15) AND (cancer OR carcinoma OR tumor OR neoplasm OR malignant). References of the literature included were also traced back.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria for research studies were as follows: (1) research conducted on any type of human cancer; (2) measuring the expression of SNHG15 in tumor tissue; (3) investigating the relationship between SNHG15 expression level and prognosis or clinicopathological characteristics; and (4) reporting the hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI), or with sufficient data available for calculation.

The exclusion criteria were as follows: (1) duplicate articles; (2) editorials, letters, expert opinions, case reports, and reviews.

The primary outcome was overall survival (OS) and recurrence-free survival (RFS). The secondary outcome was other clinicopathological characteristics (including TNM stage, lymph node metastasis, distant metastases, gender, and tumor size).

2.3. Data Collection {#sec2.3}
--------------------

Two researchers independently (Cheng Zhang and Yang Ke) extracted data from each original publication, and a third researcher (Xin Liu) resolved the differences. The extracted information included name of the first author, year of publication, country, type of cancer, sample size, the detection method for lncRNA, internal control, outcome index, and cutoff value. For studies reporting only Kaplan--Meier curves, Engauge Digitizer (version 12.1) software was used to extract survival data \[[@B31]\] and the HRs and 95% CIs were calculated using the EXCEL program file provided by Tierney et al. \[[@B32]\]. The quality of the included studies was assessed using the Newcastle--Ottawa Scale (NOS) criteria, including selection (4 points) and comparability (2 points); studies with NOS scores above 6 were considered of high quality.

2.4. Bioinformatics Analysis and Verification {#sec2.4}
---------------------------------------------

Gene Expression Profiling Interactive Analysis (GEPIA) database (<http://gepia.cancer-pku.cn/>) was used to analyze the differential expression of SNHG15 between cancer and normal tissues and the correlation of SNHG15 expression with OS of different cancer types.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analysis was performed using RevMan 5.3.3 software and Stata SE 15.1 software. HR for death or recurrence and 95% CI were calculated between the high and low SNHG15 expression group. Patients with HR  ≥ 1 indicated a poor prognosis. Furthermore, the correlation between SNHG15 expression and clinicopathological characteristics was evaluated using OR and 95% CI. Heterogeneity between the included studies was determined by the *I*^2^ value from the Cochrane Q test and the *P* value from the chi-square test. If there was heterogeneity (*I*^2^ ≥ 50% or *P* \< 0.05), the results were summarized using a random-effects model. Instead, fixed-effects models were used for analysis. Otherwise, a random-effects model was applied. Begg\'s funnel plot and Egger\'s test were used to assess publication bias. A sensitivity analysis was applied to assess the stability of the results. *P* ≤ 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of Included Studies {#sec3.1}
----------------------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, 59 articles were initially detected according to the search strategy, and 41 articles remained after removing duplicates. After carefully screening the titles and abstracts based on the inclusion and exclusion criteria, 26 articles were excluded, including reviews, conference abstracts, and unrelated studies. After reading the full text of the remaining 15 articles, 4 articles were excluded due to incomplete data. Finally, 11 studies involving 1,078 patients were included in the meta-analysis \[[@B15], [@B18], [@B19], [@B21]--[@B28]\].

All the 11 studies included were from China, with 9 different types of cancer, viz., hepatocellular carcinoma (HCC) \[[@B18]\], gastric cancer (GC) \[[@B19]\], colorectal cancer (CRC) \[[@B27]\], pancreatic cancer (PC) \[[@B21]\], non-small-cell lung cancer (NSCLC) \[[@B24]--[@B26]\], renal cell cancer (RCC) \[[@B22]\], thyroid cancer (TC) \[[@B23]\], breast cancer (BC) \[[@B25]\], and epithelial ovarian cancer (OC) \[[@B28]\]. All the included studies were tested for the expression of SNHG15 by quantitative reverse transcription PCR (qRT-PCR), but the cutoff value and the internal reference were different ([Table 1](#tab1){ref-type="table"}). HR and 95% CI could be directly extracted in 2 studies \[[@B19], [@B23]\] and were calculated from the survival curve in the remaining 9 studies using the Engauge Digitizer software \[[@B31], [@B32]\]. The characteristics of the included studies are summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Association between SNHG15 Expression and OS {#sec3.2}
-------------------------------------------------

The association between SNHG15 expression and OS was reported in the 11 studies \[[@B15], [@B18], [@B19], [@B21]--[@B28]\]. As there was no statistical heterogeneity among the 11 studies (*P*=0.99, *I*^2^ = 0%), a fixed-effects model was chosen to estimate the combined HR and 95% CI. The results showed that the HR for death between the high SNHG15 expression group and the low SNHG15 expression group was 1.96 (95% CI = 1.55--2.47, *P* \< 0.00001; see [Table 2](#tab2){ref-type="table"} and [Figure 2(a)](#fig2){ref-type="fig"}).

Given that the 11 studies reported 9 different types of cancer, we divided these studies into three subgroups, including digestive system (including HCC, CRC, GC, and PC) \[[@B18], [@B19], [@B21], [@B27]\], respiratory system (including NSCLC) \[[@B24]--[@B26]\], and other systems (including RCC, TC, BC, and OC) \[[@B15], [@B22], [@B23], [@B28]\]. Since no significant heterogeneity between different subgroup studies was detected (*I*^2^ = 0%, *P*=0.74 for digestive system, *I*^2^ = 0%, *P*=0.87 for respiratory system, and *I*^2^ = 0%, *P*=0.92 for other system), we used a fixed-effects model to complete the synthesis of the data. The results of the subgroup analysis showed that the HR and 95% CI for death between the high SNHG15 expression group and the low SNHG15 expression group in digestive, respiratory, and other cancers were 1.91 (95% CI = 1.38--2.66, *P*=0.0001), 1.83 (95% CI = 0.89--3.76, *P*=0.10), and 2.05 (95% CI = 1.41--2.97, *P*=0.0001; see [Table 2](#tab2){ref-type="table"} and [Figure 2(b)](#fig2){ref-type="fig"}). Furthermore, we also performed a series of subgroup analyses based on cutoff values and internal controls. The results showed that when GAPDH or *β*-actin was used as an internal control, or median value was used as a cutoff test, high expression of SNHG15 was significantly associated with a shorter OS (see [Table 2](#tab2){ref-type="table"}, Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}).

3.3. Association between SNHG15 Expression and RFS {#sec3.3}
--------------------------------------------------

Three studies reported the association between SNHG15 expression and RFS \[[@B19], [@B25], [@B28]\]. As there was no statistical heterogeneity among the 3 studies (*I*^2^ = 0%, *P*=0.56), a fixed-effects model was used. The combined HR for RFS between the high SNHG15 expression group and the low SNHG15 expression group was 2.03 (95% CI = 1.46--2.83, *P* \< 0.00001; see [Figure 4](#fig4){ref-type="fig"}), suggesting that an increase in SNHG15 expression was significantly associated with a shorter OS.

3.4. Association between SNHG15 Expression and Other Clinicopathological Parameters {#sec3.4}
-----------------------------------------------------------------------------------

As shown in [Table 3](#tab3){ref-type="table"}, high SNHG15 expression was associated with advanced TNM stage (OR = 3.05, 95% CI = 2.31--4.02, *P* \< 0.00001; see [Table 3](#tab3){ref-type="table"} and [Figure 5(a)](#fig5){ref-type="fig"}), lymph node metastasis (OR = 3.20, 95% CI = 2.30--4.45, *P* \< 0.00001; see [Table 3](#tab3){ref-type="table"} and [Figure 5(b)](#fig5){ref-type="fig"}), and distant metastases (OR = 5.05, 95% CI = 2.15--11.85, *P*=0.0002; see [Table 3](#tab3){ref-type="table"} and [Figure 5(c)](#fig5){ref-type="fig"}). In contrast, no statistical correlation was observed between SNHG15 expression and gender (*P*=0.30; see [Table 3](#tab3){ref-type="table"} and [Figure 5(d)](#fig5){ref-type="fig"}) and tumor size (*P*=0.77; see [Table 3](#tab3){ref-type="table"} and [Figure 5(e)](#fig5){ref-type="fig"}). Additionally, due to insufficient age-related data on tumor differentiation in the included studies, no meta-analysis was performed on the association between SNHG15 expression and these clinical-pathological parameters.

3.5. Sensitivity Analysis and Publication Bias {#sec3.5}
----------------------------------------------

As shown in [Figure 6(a)](#fig6){ref-type="fig"}, the deletion of any included studies had no significant impact on the results, suggesting that our results were reasonable and reliable.

Furthermore, we performed Begg\'s funnel plot and Egger\'s test to evaluate the publication bias of the correlation between SNHG15 expression and OS. The Begg funnel plot is shown in [Figure 6(b)](#fig6){ref-type="fig"}, and the results of the Egger test was *P*=0.409. The results indicated no significant publication bias in the studies included in this meta-analysis.

The sensitivity analysis and Begg\'s test between SNHG15 expression and RFS were also performed, and the results suggested that our results on RFS were reasonable and reliable (see Figures [S1(a)](#supplementary-material-1){ref-type="supplementary-material"} and [S1(b)](#supplementary-material-1){ref-type="supplementary-material"}).

3.6. Verification Results in the TCGA Dataset {#sec3.6}
---------------------------------------------

We evaluated the correlation between SNHG15 expression and OS in the 9 malignant tumors involved in this meta-analysis through the TCGA dataset. According to the median expression of SNHG15 in each of the 9 malignant tumors, patients with an expression level higher than the median were considered in the high-expression group, and patients with an expression level lower than the median were considered in the low-expression group. As shown in [Figure 7(a)](#fig7){ref-type="fig"}, the cancer patient population with high SNHG15 expression levels had a significantly poorer OS than those with low SNHG15 expression levels (HR = 1.2, *P*=0.012), which was consistent with our meta-analysis results. We also evaluated the correlation between SNHG15 expression and OS in digestive (including HCC, CRC, GC, and PC), respiratory (including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)) and in other (including RCC, TC, BC, and OC) malignant tumors in TCGA. The result showed that patients with high SNHG15 expression levels had significantly poorer OS than those with low SNHG15 expression levels in digestive cancers (HR = 1.3, *P*=0.00072; see [Figure 7(b)](#fig7){ref-type="fig"}) and other cancers (HR = 1.6, *P*=1.3 × 10^−7^; see [Figure 7(c)](#fig7){ref-type="fig"}). However, there was no correlation between SNHG15 expression and OS in respiratory cancers (HR = 0.94, *P*=0.58; see [Figure 7(d)](#fig7){ref-type="fig"}). In addition, we evaluated the correlation between SNHG15 expression and other clinicopathological parameters in the 9 malignant tumors through the TCGA dataset. Consistent with our meta-analysis results, high SNHG15 expression was associated with advanced TNM stage (*P*=0.014; see [Table 4](#tab4){ref-type="table"}), lymph node metastasis (*P* \< 0.001; [Table 4](#tab4){ref-type="table"}), and distant metastases (*P* \< 0.001; see [Table 4](#tab4){ref-type="table"}), while no significant correlation was observed between SNHG15 expression and gender (*P*=0.637; see [Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

This study provides for the first time a systematic analysis of the relationship between SNHG15 expression and prognosis of patients with different types of cancer. The most important finding in this meta-analysis is that high expression of the long noncoding RNA SNHG15 in cancer tissues predicts an unfavorable prognosis for cancer patients. SNHG15 is one of the newly discovered popular lncRNAs involved in the development and progression of many malignant tumors. SNHG15 was first identified as a lncRNA with a short half-life in a cell stress response study \[[@B33]\]. Since then, a large number of studies have reported that SNHG15 is highly expressed in various malignant tumors, including GC, BC, CRC, HCC, NSCLC, TC, and OV \[[@B15], [@B18], [@B23], [@B25], [@B27], [@B28]\]. Furthermore, the high expression of SNHG15 is associated with poor prognosis of patients with different types of cancer \[[@B18], [@B22], [@B25]\].

Some molecular mechanisms were revealed by which SNHG15 acts as an oncogene. In the nucleus, SNHG15 can interact with the zinc finger domain of Slug, inhibiting Slug ubiquitination, and then the redundant Slug proteins inhibit E-cadherin transcription, promote the epithelial--mesenchymal transition (EMT), and stimulate the invasion and metastasis of the colon, breast, and renal cancer cells \[[@B22], [@B34]\]. In pancreatic cancer, SNHG15 can also bind to the enhancer of zeste homolog 2 and inhibit the expression of p15 and the Kruppel-like factor 2 by zeste homolog 2-mediated H3 lysine 27 trimethylation modification and finally promote the proliferation of pancreatic cancer cells \[[@B20]\]. In the cytoplasm, SNHG15 can also act as the competing endogenous RNA and competitively bind to a variety of microRNAs, influence the expression of multiple invasion related proteins, and thereby promote the proliferation, invasion, and migration of malignant tumor cells \[[@B35]\]. For example, in osteosarcoma, SNHG15 can directly bind miR-141 as a "molecular sponge" to promote osteosarcoma expression and cancer growth \[[@B36]\].

Different cancers display distinct clinical characteristics and biological behaviors. To reduce the heterogeneity between studies, a subgroup study was performed based on pathological classification. The results suggested that the increase of SNHG15 expression in the digestive subgroup (including HCC, CRC, GC, and PC) and RCC, TC, BC, and OC subgroup was significantly associated with a shorter OS, which suggested that SNHG15 may be a reliable prognostic biomarker for cancers of the digestive, urinary, thyroid, and reproductive organs. However, there was no significant correlation detected between SNHG15 and NSCLC.

Chemotherapy is a main treatment approach for various cancers. Previous studies have found that SNHG15 expression contributes to cisplatin resistance in BC \[[@B37]\] and temozolomide resistance in glioma \[[@B38]\]. In the present study, we found that SNHG15 expression correlated with lymphatic metastasis, distant metastasis, and later TNM stages, suggesting that (1) increased expression of SNHG15 may be closely related to the advanced characteristics of cancer; (2) clarification of the relationships between SNHG15 expression and clinical parameters may allow the identification of the patient population who can potentially benefit from chemotherapy.

Our study included a large number of samples, which confers a high statistical power. Therefore, the results of the present study are more stable and accurate than those of previous individual studies. However, some limitations should be noted in this meta-analysis. First, all studies were from China, so we used the TCGA database, which includes cancer cases from multiple regions including African American, American native, and Caucasian, to verify our meta-analysis results. Indeed, the bioinformatics results support our meta-analysis. A large sample size with multiple races is needed to confirm our findings in the future. Second, given the fact that individual patient data were not analyzed, certain data on the relationships between clinical parameters and SNHG15 could not be combined.

5. Conclusions {#sec5}
==============

In conclusion, this is the first meta-analysis reporting that LncRNA SNHG15 can be used as a prognostic biomarker for cancer patients, especially cancers in the digestive, urinary, thyroid, and reproductive systems. In addition, the high expression level of SNHG15 was closely related to the advanced characteristics of cancer, indicating that patients without these advanced characteristics may be prime candidates for chemotherapy. More high-quality and large-sample studies are required to further confirm the prognostic role of SNHG15 in cancer.
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###### 

Figure S1: sensitivity analysis and publication bias. (a) Sensitivity analysis of the association between SNHG15 expression and association and recurrence-free survival (RFS). (b) Begg\'s funnel plot of publication bias for RFS.

###### 

Click here for additional data file.

![Flow diagram of the study search and selection.](JO2020-3417036.001){#fig1}

![Forest plot for the association between SNHG15 expression and OS in (a) all cancer patients and (b) subgroup analysis based on different cancer types.](JO2020-3417036.002){#fig2}

![Forest plot for the association between SNHG15 expression and OS in a subgroup analysis based on (a) internal control and (b) cutoff.](JO2020-3417036.003){#fig3}

![Forest plot for association between SNHG15 expression and RFS.](JO2020-3417036.004){#fig4}

![Forest plots for the association between SNHG15 expression and (a) TNM stage (III-IV vs. I-II), (b) lymph node metastasis (yes vs. no), (c) distant metastasis (yes vs. no), (d) gender (male vs. female), and (e) tumor size (\>5 cm vs. ≤5 cm).](JO2020-3417036.005){#fig5}

![Sensitivity analysis and publication bias. (a) Sensitivity analysis of the association between SNHG15 expression and OS. (b) Begg\'s funnel plot of publication bias for OS.](JO2020-3417036.006){#fig6}

![Validation of SNHG15 in the TCGA dataset. (a) Survival curves of SNHG15 are plotted for 9 kinds of cancers involved in this meta-analysis from the TCGA dataset. (b) Survival curves of SNHG15 are plotted for digestive cancers, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC), and pancreatic cancer (PC), from the TCGA dataset. (c) Survival curves of SNHG15 are plotted for other cancers, including renal cell cancer (RCC), thyroid cancer (TC), breast cancer (BC), and epithelial ovarian cancer (OC), from the TCGA dataset. (d) Survival curves of SNHG15 are plotted for non-small-cell lung cancer, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), from the TCGA dataset.](JO2020-3417036.007){#fig7}

###### 

Characteristics of the studies included in the meta-analysis.

  Study                     Year   Country   Cancer type   Detection method   Internal control   Cutoff   Total sample   Expression   Tumor stage   Metastasis analysis   Outcome   HR estimation   NOS score   
  ------------------------- ------ --------- ------------- ------------------ ------------------ -------- -------------- ------------ ------------- --------------------- --------- --------------- ----------- ---
  Zhang et al. \[[@B18]\]   2016   China     HCC           qRT-PCR            GAPDH              Median   152            77           75            I--IV                 N/A       OS              SC          8
  Chen et al. \[[@B19]\]    2016   China     GC            qRT-PCR            GAPDH              Median   106            53           53            I--IV                 DM/LNM    OS/RFS          Reported    7
  Gou et al. \[[@B21]\]     2018   China     PC            qRT-PCR            GAPDH              Median   171            82           89            I--IV                 LNM       OS              SC          8
  Du et al. \[[@B22]\]      2018   China     RCC           qRT-PCR            *β*-Actin          Median   96             47           52            T1--T4                N/A       OS              SC          7
  Wu et al. \[[@B23]\]      2018   China     TC            qRT-PCR            GAPDH              Median   92             50           42            I--IV                 LNM       OS              Reported    9
  Cui et al. \[[@B24]\]     2018   China     NSCLC         qRT-PCR            GAPDH              FC       55             28           27            I--IV                 LNM       OS              SC          7
  Dong et al. \[[@B25]\]    2018   China     NSCLC         qRT-PCR            GAPDH              Median   49             23           26            I--IV                 LNM       OS/RFS          SC          7
  Jin et al. \[[@B26]\]     2018   China     NSCLC         qRT-PCR            GAPDH              FC       35             20           15            I--III                LNM       OS              SC          8
  Kong and Qiu \[[@B15]\]   2018   China     BC            qRT-PCR            GAPDH              Median   58             29           29            I--IV                 LNM       OS              SC          7
  Huang et al. \[[@B27]\]   2019   China     CRC           qRT-PCR            GAPDH              Median   91             46           45            I--IV                 DM/LNM    OS              SC          8
  Qu et al. \[[@B28]\]      2019   China     OC            qRT-PCR            GAPDH              Median   182            73           109           I--IV                 N/A       OS/RFS          SC          8

HCC: hepatocellular carcinoma; GC: gastric cancer; PC: pancreatic ductal cancer; RCC: renal cell carcinoma; TC: thyroid carcinoma; NSCLC, non-small-cell lung cancer; BC: breast cancer; CRC: colorectal cancer; EOC: epithelial ovarian cancer; qRT-PCR: quantitative reverse transcription PCR; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; FC: fold change; LNM: lymph node metastasis; DM: distant metastasis; N/A: not available; OS: overall survival; SC: survival curve; RFS: recurrence -free survival; HR: hazard ratio; and NOS: Newcastle--Ottawa Scale.

###### 

Subgroup meta-analysis of HRs for death.

  Categories            Study number \[references\]                                            Total sample   *P* value   HR (95% CI) for OS   Heterogeneity   Model   
  --------------------- ---------------------------------------------------------------------- -------------- ----------- -------------------- --------------- ------- -------
  OS                    11 \[[@B15], [@B18], [@B19], [@B21]--[@B28]\]                          1087           \<0.00001   1.96 (1.55--2.47)    0               0.99    Fixed
  Cancer type                                                                                                                                                           
   Digestive system     4 \[[@B18], [@B19], [@B21], [@B27]\]                                   520            0.0001      1.91 (1.38--2.66)    0               0.74    Fixed
   Respiratory system   3 \[[@B24]--[@B26]\]                                                   139            0.1         1.83 (0.89--3.76)    0               0.87    Fixed
   Other systems        4 \[[@B15], [@B22], [@B23], [@B28]\]                                   428            0.0001      2.05 (1.41--2.97)    0               0.92    Fixed
  Internal control                                                                                                                                                      
   GAPDH                10 \[[@B15], [@B18], [@B19], [@B21], [@B23]--[@B28]\]                  991            \<0.00001   1.92 (1.51--2.45)    0               0.99    Fixed
   *β*-Actin            1 \[[@B22]\]                                                           96             0.0479      2.48 (1.01--6.12)    N/A             N/A     N/A
  Cutoff                                                                                                                                                                
   Median               9 \[[@B15], [@B18], [@B19], [@B21]--[@B23], [@B25], [@B27], [@B28]\]   997            \<0.00001   1.98 (1.55--2.52)    0               0.98    Fixed
   Fold change          2 \[[@B24], [@B26]\]                                                   90             0.21        1.72 (0.73--4.04)    0               0.65    Fixed

OS: overall survival; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HR: hazard ratio; and N/A: not applicable.

###### 

Meta-analysis of the association between SNHG15 expression and clinicopathological parameters.

  Clinicopathological parameters       Study number \[references\]                            Total sample   *P* value   OR (95% CI) for OS   Heterogeneity   Model   
  ------------------------------------ ------------------------------------------------------ -------------- ----------- -------------------- --------------- ------- --------
  Gender (male vs. female)             9 \[[@B18], [@B19], [@B21]--[@B27]\]                   847            0.30        0.87 (0.66--1.14)    30              0.18    Fixed
  Tumor size (\>5 cm vs. ≤5 cm)        3 \[[@B18], [@B19], [@B25]\]                           317            0.77        1.17 (0.41--3.36)    78              0.01    Random
  TNM stage (III-IV vs. I-II)          9 \[[@B15], [@B18], [@B19], [@B22]--[@B25], [@B27]\]   999            \<0.00001   3.05 (2.31--4.02)    0               0.82    Fixed
  Lymph node metastasis (yes vs. no)   8 \[[@B15], [@B19], [@B21], [@B23]--[@B27]\]           657            \<0.00001   3.20 (2.30--4.45)    0               0.87    Fixed
  Distant migration (yes vs. no)       2 \[[@B19], [@B27]\]                                   197            0.0002      5.05 (2.15--11.85)   0               0.43    Fixed

OR: odds ratio; OS: overall survival; and CI: confidence interval.

###### 

Correlation between SNHG15 expression and other clinicopathological parameters in TCGA.

  ---------------------------------------------------------------------------------------------
  Clinicopathological parameters   Number of cases\   SNHG15 expression   *P* value   
                                   (*n* = 3430)                                       
  -------------------------------- ------------------ ------------------- ----------- ---------
  Gender                                                                              0.637

   Male                            1734               896                 838          

   Female                          1696               891                 805          

  TNM stage                                                                           0.014

   III-IV                          1090               602                 488          

   I-II                            2340               1185                1155         

  Lymph node metastasis                                                               \<0.001

   Yes                             1593               996                 597          

   No                              1837               791                 1046         

  Distant migration                                                                   \<0.001

   Yes                             215                161                 54           

   No                              3215               1626                1589         
  ---------------------------------------------------------------------------------------------

Median expression level was used as the cutoff. For analysis of the correlation between SNHG15 levels and clinical features, Pearson\'s chi-square tests were used. Results were considered statistically significant at *P* \< 0.05.

[^1]: Academic Editor: Reza Izadpanah
